Cargando…

Tackling challenges of TB/MDRTB in China: concerted actions are imperative

China is the second largest TB epidemic with the most number of people infected with multi-drug resistant (MDR). Over the past decade, a large number of TB control projects have been funded by the government of China and international organizations, and epidemic in China has been effectively control...

Descripción completa

Detalles Bibliográficos
Autor principal: Tang, Shenglan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407541/
https://www.ncbi.nlm.nih.gov/pubmed/25908975
http://dx.doi.org/10.1186/s40249-015-0050-4
_version_ 1782367926001598464
author Tang, Shenglan
author_facet Tang, Shenglan
author_sort Tang, Shenglan
collection PubMed
description China is the second largest TB epidemic with the most number of people infected with multi-drug resistant (MDR). Over the past decade, a large number of TB control projects have been funded by the government of China and international organizations, and epidemic in China has been effectively controlled. However TB control in China still faced many challenges. Strategies to address these challenges may include integrating the national TB control program into health insurance schemes, strengthening TB case management through involving the Chinese hospital in national TB control program, and reforming payment methods for TB care as part of health system reform in China. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40249-015-0050-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4407541
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44075412015-04-24 Tackling challenges of TB/MDRTB in China: concerted actions are imperative Tang, Shenglan Infect Dis Poverty Commentary China is the second largest TB epidemic with the most number of people infected with multi-drug resistant (MDR). Over the past decade, a large number of TB control projects have been funded by the government of China and international organizations, and epidemic in China has been effectively controlled. However TB control in China still faced many challenges. Strategies to address these challenges may include integrating the national TB control program into health insurance schemes, strengthening TB case management through involving the Chinese hospital in national TB control program, and reforming payment methods for TB care as part of health system reform in China. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40249-015-0050-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-16 /pmc/articles/PMC4407541/ /pubmed/25908975 http://dx.doi.org/10.1186/s40249-015-0050-4 Text en © Tang; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Tang, Shenglan
Tackling challenges of TB/MDRTB in China: concerted actions are imperative
title Tackling challenges of TB/MDRTB in China: concerted actions are imperative
title_full Tackling challenges of TB/MDRTB in China: concerted actions are imperative
title_fullStr Tackling challenges of TB/MDRTB in China: concerted actions are imperative
title_full_unstemmed Tackling challenges of TB/MDRTB in China: concerted actions are imperative
title_short Tackling challenges of TB/MDRTB in China: concerted actions are imperative
title_sort tackling challenges of tb/mdrtb in china: concerted actions are imperative
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407541/
https://www.ncbi.nlm.nih.gov/pubmed/25908975
http://dx.doi.org/10.1186/s40249-015-0050-4
work_keys_str_mv AT tangshenglan tacklingchallengesoftbmdrtbinchinaconcertedactionsareimperative